Astria Therapeutics
ATXS
ATXS
68 hedge funds and large institutions have $171M invested in Astria Therapeutics in 2023 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 27 increasing their positions, 18 reducing their positions, and 12 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
less ownership
Funds ownership: →
less funds holding
Funds holding: →
17% less capital invested
Capital invested by funds: $205M → $171M (-$34M)
40% less call options, than puts
Call options by funds: $61K | Put options by funds: $102K
67% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 12
Holders
68
Holding in Top 10
1
Calls
$61K
Puts
$102K
Top Buyers
| 1 | +$4.34M | |
| 2 | +$2.79M | |
| 3 | +$2.61M | |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$1.25M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$817K |
Top Sellers
| 1 | -$8.33M | |
| 2 | -$4.92M | |
| 3 | -$2.96M | |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$2.54M |
| 5 |
Millennium Management
New York
|
-$2.3M |